12:00 AM
 | 
Sep 27, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Pasireotide: Phase III data

Novartis said the data will form the basis for its first regulatory filing for the compound, which is expected by year end. Pasireotide has Orphan Drug designation in the U.S. and EU for the indication.

Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland
Product: Pasireotide ( SOM230)
Business: Other
Molecular target: Somatostatin...

Read the full 258 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >